In casualty insurance, providing for coverage for prostate cancer screening.
Summary
SB447 would amend Pennsylvania’s Insurance Company Law of 1921 to require health insurance policies offered, issued, or renewed in the Commonwealth to cover the full cost of prostate cancer screening for certain high-risk individuals. The mandate applies to covered persons age 40 and older who are at elevated risk because of a family history of prostate cancer, a genetic alteration or related cancer in the person or a first-degree relative, or other factors when a physician determines early detection is medically appropriate.
The bill specifies that covered prostate cancer screening expenses must be provided at least annually and cannot be subject to cost-sharing. It defines key terms such as cost-sharing, family history, first-degree relative, and prostate cancer screening, and it expressly includes PSA tests and digital rectal examinations within the covered screenings. The bill also sets delayed applicability rules for policies that require rate or form filings and for policies that do not, with the act taking effect 60 days after enactment.
Impact
SB447 would create a new insurance coverage mandate in Pennsylvania law by adding Section 635.11 to the Insurance Company Law of 1921. Health insurers would be required to cover prostate cancer screening for specified high-risk enrollees without deductibles, copayments, coinsurance, or similar out-of-pocket charges, which would likely affect benefit design, premium calculations, and claims administration for individual, group, and other health insurance policies subject to the statute. The bill would also establish a statutory definition framework for the new benefit and set implementation timing based on policy filing requirements.
Sentiment
Based on the bill text and the available context, the measure appears to be framed as a preventive health coverage expansion with no recorded committee debate or votes in the provided materials. The sponsorship by a bipartisan group of senators suggests at least some cross-party support or interest in the proposal. Overall, the bill’s tone is pro-screening and pro-access, with the apparent policy goal of encouraging early detection of prostate cancer among higher-risk populations.
Contention
The main policy issue likely to generate discussion is the insurance mandate itself, especially the requirement that screening be covered without cost-sharing, which can raise concerns about insurer costs and premium impacts. Another possible point of contention is the age threshold and risk-based eligibility criteria, including the use of physician judgment for “other factors,” which could affect how broadly the benefit is applied. No specific objections, amendments, or recorded opposition appear in the provided committee or voting history.